Genome-wide approaches to identify pharmacogenetic contributions to adverse drug reactions

Pharmacogenomics Journal

Volumn 9, Issue 1, 2009, Pages 23-33

  Nelson, M R ^a   Bacanu, S A ^a   Mosteller, M ^a   Li, L ^a   Bowman, C E ^a   Roses, A D ^a   Lai, E H ^a   Ehm, M G ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ALLOPURINOL; CARBAMAZEPINE; GEFITINIB; HLA B ANTIGEN; IRINOTECAN; ISONIAZID; MERCAPTOPURINE; TRANILAST;

ADVERSE DRUG REACTION; ARTICLE; CONTROLLED STUDY; DIARRHEA; DRUG HYPERSENSITIVITY; GENE FREQUENCY; GENETIC RISK; GENOTYPE; HUMAN; HYPERBILIRUBINEMIA; LIVER TOXICITY; NEUTROPENIA; PHARMACOGENETICS; POWER ANALYSIS; PREDICTION; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; SEQUENTIAL ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; SKIN MANIFESTATION; STEVENS JOHNSON SYNDROME; UNSPECIFIED SIDE EFFECT;

CLINICAL TRIALS AS TOPIC; DIDEOXYNUCLEOSIDES; DNA; DRUG HYPERSENSITIVITY; DRUG TOXICITY; GENOME, HUMAN; HLA-B ANTIGENS; HUMANS; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 59149089672     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/tpj.2008.4     Document Type: Article

References (42)

1. Edwards IR, Aronson JK. Adverse drug reactions: Definitions, diagnosis, and management. Lancet 2000; 356: 1255-1259.
2. Dimasi JA. Risks in new drug development: Approval success rates for investigational drugs. Clin Pharmacol Ther 2001; 69: 297-307.
3. Wysowski DK, Swartz L. Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: The importance of reporting suspected reactions. Arch Intern Med 2005; 165: 1363-1369.
4. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: A meta-analysis of prospective studies. JAMA 1998; 279: 1200-1205.
5. Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ et al. Adverse drug reactions as cause of admission to hospital: Prospective analysis of 18 820 patients. BMJ 2004; 329: 15-19.
6. Cusatis G, Gregorc V, Li J, Spreafico A, Ingersoll RG, Verweij J et al. Pharmacogenetics of ABCG2 and adverse reactions to gefitinib. J Natl Cancer Inst 2006; 98: 1739-1742.
7. Huang YS, Chern HD, Su WJ, Wu JC, Chang SC, Chiang CH et al. Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug-induced hepatitis. Hepatology 2003; 37: 924-930.
8. Innocenti F, Undevia SD, Iyer L, Chen PX, Das S, Kocherginsky M et al. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol 2004; 22: 1382-1388.
9. Rouits E, Boisdron-Celle M, Dumont A, Guerin O, Morel A, Gamelin E. Relevance of different UGT1A1 polymorphisms in irinotecan-induced toxicity: A molecular and clinical study of 75 patients. Clin Cancer Res 2004; 10: 5151-5159.
10. Hetherington S, Hughes AR, Mosteller M, Shortino D, Baker KL, Spreen W et al. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet 2002; 359: 1121-1122.
11. Danoff TM, Campbell DA, McCarthy LC, Lewis KF, Repasch MH, Saunders AM et al. A Gilbert's syndrome UGT1A1 variant confers susceptibility to tranilast-induced hyperbilirubinemia. Pharmacogenomics J 2004; 4: 49-53.
12. Relling MV, Hancock ML, Rivera GK, Sandlund JT, Ribeiro RC, Krynetski EY et al. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J Natl Cancer Inst 1999; 91: 2001-2008.
13. Hung SI, Chung WH, Liou LB, Chu CC, Lin M, Huang HP et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci USA 2005; 102: 4134-4139.
14. Chung WH, Hung SI, Hong HS, Hsih MS, Yang LC, Ho HC et al. Medical genetics: A marker for Stevens-Johnson syndrome. Nature 2004; 428: 486.
15. Roses AD, Burns DK, Chissoe S, Middleton L, Jean PS. Disease-specific target selection: A critical first step down the right road. Drug Discov Today 2005; 10: 177-189.
16. Moskvina V, Holmans P, Schmidt KM, Craddock N. Design of case-controls studies with unscreened controls. Ann Hum Genet 2005; 69: 566-576.
17. Hughes AR, Mosteller M, Bansal AT, Davies K, Haneline SA, Lai EH et al. Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some, but not all, populations. Pharmacogenomics 2004; 5: 203-211.
18. Mallal S, Nolan D, Witt C, Masel G, Martin AM, Moore C et al. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 2002; 359: 727-732.
19. De Bakker PI, McVean G, Sabeti PC, Miretti MM, Green T, Marchini J et al. A high-resolution HLA and SNP haplotype map for disease association studies in the extended human MHC. Nat Genet 2006; 38: 1166-1172.
20. Whitehead J. The Design and Analysis of Sequential Clinical Trials Wiley: Chichester, 1997.
21. Jennison C, Turnbull BW. Group Sequential Methods with Applications to Clinical Trials. Chapman and Hall/CRC: Boca Raton, 2000.
22. Pe'er I, De Bakker PI, Maller J, Yelensky R, Altshuler D, Daly MJ. Evaluating and improving power in whole-genome association studies using fixed marker sets. Nat Genet 2006; 38: 663-667.
23. Marchini J, Howie B, Myers S, McVean G, Donnelly P. A new multipoint method for genome-wide association studies by imputation of genotypes. Nat Genet 2007; 39: 906-913.
24. Kruglyak L, Nickerson DA. Variation is the spice of life. Nat Genet 2001; 27: 234-236.
25. Church GM. Genomes for All. Scientific American, January, 46-54 2006.
26. Efron B, Tibshirani RJ. An Introduction to the Bootstrap. Chapman & Hall: New York, 1993.
27. Benjamini Y, Hochberg Y. Controlling the false discovery rate: A practical and powerful approach to multiple testing. J Roy Statist Soc B 1995; 57: 289-300.
28. Storey JD, Tibshirani R. Statistical significance for genomewide studies. Proc Natl Acad Sci USA 2003; 100: 9440-9445.
29. Wellcome Trust Case Control Consortium. Genome-wide association study of 14 000 cases of seven common diseases and 3000 shared controls. Nature 2007; 447: 661-678.
30. Pritchard JK, Stephens M, Donnelly P. Inference of population structure using multilocus genotype data. Genetics 2000; 155: 945-959.
31. Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich D. Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet 2006; 38: 904-909.
32. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D et al. PLINK: A tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 2007; 81: 559-575.
33. Farahani P, Levine M. Pharmacovigilance in a genomic era. Pharmacogenomics J 2006; 6: 158-161.
34. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001; 286: 954-959.
35. Vittinghoff E, Bauer DC. Case-only analysis of treatment-covariate interactions in clinical trials. Biometrics 2006; 62: 769-776.
36. Ahmadi KR, Weale ME, Xue ZY, Soranzo N, Yarnall DP, Briley JD et al. A single-nucleotide polymorphism tagging set for human drug metabolism and transport. Nat Genet 2005; 37: 84-89.
37. Cleveland WS, Grosse E, Shyu WM. Local Regression Models in Statistical Models in S. Wadsworth & Brooks/Cole: Pacific Grove, 1992.
38. R Development Core Team. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing: Vienna, Austria, 2003.
39. Weir BS. Genetic Data Analysis II: Methods for Discrete Population Genetic Data. Sinauer Associates: Sunderland, MA, 1996.
40. Mehta CR, Patel NR. A Network Algorithm for performing Fisher's exact test in r x c contingency tables. J Acoust Soc Am 1983; 78: 427-434.
41. Piantadosi S. Clinical Trials: A Methodological Perspective. John Wiley & Sons: Hoboken, NJ, 2005.
42. Lan KKG, DeMets DL. Discrete sequential boundaries for clinical trials. Biometrika 1983; 70: 659-663.